Literature DB >> 24345222

The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Claudia F Lucchinetti1, Yong Guo, Bogdan F Gh Popescu, Kazuo Fujihara, Yasuto Itoyama, Tatsuro Misu.   

Abstract

Neuromyelitis optica (NMO) is a disabling autoimmune astrocytopathy characterized by typically severe and recurrent attacks of optic neuritis and longitudinally extensive myelitis. Until recently, NMO was considered an acute aggressive variant of multiple sclerosis (MS), despite the fact that early studies postulated that NMO and MS may be two distinct diseases with a common clinical picture. With the discovery of a highly specific serum autoantibody (NMO-IgG), Lennon and colleagues provided the first unequivocal evidence distinguishing NMO from MS and other central nervous system (CNS) inflammatory demyelinating disorders. The target antigen of NMO-IgG was confirmed to be aquaporin-4 (AQP4), the most abundant water channel protein in the CNS, mainly expressed on astrocytic foot processes at the blood-brain barrier, subpial and subependymal regions. Pathological studies demonstrated that astrocytes were selectively targeted in NMO as evidenced by the extensive loss of immunoreactivities for the astrocytic proteins, AQP4 and glial fibrillary acidic protein (GFAP), as well as perivascular deposition of immunoglobulins and activation of complement even within lesions with a relative preservation of myelin. In support of these pathological findings, GFAP levels in the cerebrospinal fluid (CSF) during acute NMO exacerbations were found to be remarkably elevated in contrast to MS where CSF-GFAP levels did not substantially differ from controls. Additionally, recent experimental studies showed that AQP4 antibody is pathogenic, resulting in selective astrocyte destruction and dysfunction in vitro, ex vivo and in vivo. These findings strongly suggest that NMO is an autoimmune astrocytopathy where damage to astrocytes exceeds both myelin and neuronal damage. This chapter will review recent neuropathological studies that have provided novel insights into the pathogenic mechanisms, cellular targets, as well as the spectrum of tissue damage in NMO.
© 2013 International Society of Neuropathology.

Entities:  

Keywords:  aquaporin-4 (AQP4); astrocytopathy; neuromyelitis optica (NMO)

Mesh:

Substances:

Year:  2014        PMID: 24345222      PMCID: PMC3905574          DOI: 10.1111/bpa.12099

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  114 in total

1.  Neuromyelitis optica preceded by hyperCKemia episode.

Authors:  N Suzuki; T Takahashi; M Aoki; T Misu; S Konohana; T Okumura; H Takahashi; S Kameya; K Yamaki; T Kumagai; K Fujihara; Y Itoyama
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study.

Authors:  R Takano; T Misu; T Takahashi; S Sato; K Fujihara; Y Itoyama
Journal:  Neurology       Date:  2010-07-20       Impact factor: 9.910

3.  Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.

Authors:  Makoto Kinoshita; Yuji Nakatsuji; Takashi Kimura; Masayuki Moriya; Kazushiro Takata; Tatsusada Okuno; Atsushi Kumanogoh; Koji Kajiyama; Hiroo Yoshikawa; Saburo Sakoda
Journal:  Biochem Biophys Res Commun       Date:  2010-02-25       Impact factor: 3.575

4.  Schwann cell migration is integrin-dependent and inhibited by astrocyte-produced aggrecan.

Authors:  Fardad T Afshari; Jessica C Kwok; Linda White; James W Fawcett
Journal:  Glia       Date:  2010-05       Impact factor: 7.452

Review 5.  Inflammasome signaling at the heart of central nervous system pathology.

Authors:  Swarupa Chakraborty; Deepak Kumar Kaushik; Malvika Gupta; Anirban Basu
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 6.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

7.  Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.

Authors:  Jeffrey L Bennett; Chiwah Lam; Sudhakar Reddy Kalluri; Philippe Saikali; Katherine Bautista; Cecily Dupree; Magdalena Glogowska; David Case; Jack P Antel; Gregory P Owens; Don Gilden; Stefan Nessler; Christine Stadelmann; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

8.  Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

Authors:  Monika Bradl; Tatsuro Misu; Toshiyuki Takahashi; Mitsutoshi Watanabe; Simone Mader; Markus Reindl; Milena Adzemovic; Jan Bauer; Thomas Berger; Kazuo Fujihara; Yasuto Itoyama; Hans Lassmann
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

9.  Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Authors:  Samira Saadoun; Patrick Waters; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Brain       Date:  2010-01-04       Impact factor: 13.501

10.  Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report.

Authors:  Zeljka Petelin Gadze; Sanja Hajnsek; Silvio Basic; Davor Sporis; Goran Pavlisa; Sibila Nankovic
Journal:  BMC Neurol       Date:  2009-10-23       Impact factor: 2.474

View more
  109 in total

1.  Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?

Authors:  Sean J Pittock
Journal:  Nat Rev Neurol       Date:  2016-02-05       Impact factor: 42.937

Review 2.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

Review 3.  Differential Diagnosis of Acute Myelopathies: An Update.

Authors:  M Nichtweiß; S Weidauer
Journal:  Clin Neuroradiol       Date:  2015-06-02       Impact factor: 3.649

4.  Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS.

Authors:  Yaou Liu; Yunyun Duan; Jing Huang; Zhuoqiong Ren; Zheng Liu; Huiqing Dong; Florian Weiler; Horst K Hahn; Fu-Dong Shi; Helmut Butzkueven; Frederik Barkhof; Kuncheng Li
Journal:  Eur Radiol       Date:  2017-06-30       Impact factor: 5.315

5.  Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.

Authors:  Laura Azzopardi; Amanda L Cox; Claire L McCarthy; Joanne L Jones; Alasdair J Coles
Journal:  J Neurol       Date:  2016-01       Impact factor: 4.849

Review 6.  Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.

Authors:  Deena A Tajfirouz; M Tariq Bhatti; John J Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

7.  Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis.

Authors:  Russell C Dale
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

8.  Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  Tetsuya Akaishi; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Juichi Fujimori; Yoshiki Takai; Shuhei Nishiyama; Michiaki Abe; Tadashi Ishii; Masashi Aoki; Ichiro Nakashima
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 4.849

9.  Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4.

Authors:  Sharon A Sagan; Ryan C Winger; Andrés Cruz-Herranz; Patricia A Nelson; Sarah Hagberg; Corey N Miller; Collin M Spencer; Peggy P Ho; Jeffrey L Bennett; Michael Levy; Marc H Levin; Alan S Verkman; Lawrence Steinman; Ari J Green; Mark S Anderson; Raymond A Sobel; Scott S Zamvil
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-08       Impact factor: 11.205

10.  Expanding the range of immunopathology in neuromyelitis optica spectrum disorder.

Authors:  Jennifer Massey; Michael E Buckland; Yael Barnett; Ian Sutton
Journal:  BMJ Case Rep       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.